Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis
Por:
Montes, A, Perez-Pampin, E, Narvaez, J, Canete, JD, Navarro-Sarabia, F, Moreira, V, Fernandez-Nebro, A, Ordonez, MD, de la Serna, AR, Magallares, B, Vasilopoulos, Y, Sarafidou, T, Caliz, R, Ferrer, MA, Joven, B, Carreira, P, Gomez-Reino, JJ, Gonzalez, A
Publicada:
1 may 2014
Resumen:
Objectives
We aimed to assess a functional polymorphism in FCGR2A H131R, for association with the treatment response to Fc-containing inhibitors of tumor necrosis factor (TNF).
Methods
A total of 429 biologic-naive patients with rheumatoid arthritis collected in two sets (299 and 130) were treated during standard care with infliximab (INX), etanercept, or adalimumab. Response to the treatment was evaluated at 3, 6, and 12 months of follow-up as the change in the Disease Activity Score (DAS) 28 from baseline and as the response by the European League Against Rheumatism (EULAR) criteria. These variables were analyzed for association with linear and logistic regression models that included sex, inhibitors of TNF, and baseline DAS28 as covariates.
Results
Significant association was found between the FCGR2A H131R polymorphism and the response to treatment with INX, but not with the other two TNF inhibitors. The 131R allele was associated with a lower change in DAS28 (P=0.04-0.008 at different times) in the first set of patients and confirmed in the second group of patients (P=0.026 at 3 months of follow-up). Association was also found in the comparison between nonresponders and responders to INX by the EULAR criteria.
Conclusion
We found an association of the FCGR2A 131R allele with poor response to INX. This finding could be of utility to understand the mechanisms behind treatment failure and contribute to biomarker panels for INX response prediction.
Filiaciones:
Montes, A:
Hosp Clin Univ Santiago, Inst Invest Sanitaria, Lab Invest 10, Santiago De Compostela 15706, Spain
Univ Clin Hosp Santiago, Hlth Res Inst, Rheumatol Unit, Santiago De Compostela 15706, Spain
Perez-Pampin, E:
Hosp Clin Univ Santiago, Inst Invest Sanitaria, Lab Invest 10, Santiago De Compostela 15706, Spain
Univ Clin Hosp Santiago, Hlth Res Inst, Rheumatol Unit, Santiago De Compostela 15706, Spain
Narvaez, J:
Univ Hosp Bellvitge, Rheumatol Unit, Barcelona, Spain
Canete, JD:
Univ Hosp Clin, Rheumatol Unit, Barcelona, Spain
Navarro-Sarabia, F:
Univ Hosp Virgen Macarena, Rheumatol Unit, Seville, Spain
Moreira, V:
Univ Hosp Virgen Macarena, Rheumatol Unit, Seville, Spain
Fernandez-Nebro, A:
Univ Malaga, Biomed Res Inst Malaga, Univ Reg Hosp Malaga, UGC Rheumatol, E-29071 Malaga, Spain
Ordonez, MD:
Univ Malaga, Biomed Res Inst Malaga, Univ Reg Hosp Malaga, UGC Rheumatol, E-29071 Malaga, Spain
de la Serna, AR:
Hosp Santa Creu & Sant Pau, Rheumatol Unit, Barcelona, Spain
Magallares, B:
Hosp Santa Creu & Sant Pau, Rheumatol Unit, Barcelona, Spain
Vasilopoulos, Y:
Univ Thessaly, Dept Biochem & Biotechnol, Larisa, Greece
Sarafidou, T:
Univ Thessaly, Dept Biochem & Biotechnol, Larisa, Greece
Caliz, R:
Univ Hosp Virgen de las Nieves, Rheumatol Unit, Granada, Spain
Ferrer, MA:
Univ Hosp Virgen de las Nieves, Rheumatol Unit, Granada, Spain
Joven, B:
Hosp 12 October, Rheumatol Unit, Madrid, Spain
Carreira, P:
Hosp 12 October, Rheumatol Unit, Madrid, Spain
Gomez-Reino, JJ:
Hosp Clin Univ Santiago, Inst Invest Sanitaria, Lab Invest 10, Santiago De Compostela 15706, Spain
Univ Clin Hosp Santiago, Hlth Res Inst, Rheumatol Unit, Santiago De Compostela 15706, Spain
Univ Santiago de Compostela, Dept Med, Santiago De Compostela, Spain
Gonzalez, A:
Hosp Clin Univ Santiago, Inst Invest Sanitaria, Lab Invest 10, Santiago De Compostela 15706, Spain
Univ Clin Hosp Santiago, Hlth Res Inst, Rheumatol Unit, Santiago De Compostela 15706, Spain
|